-
Recent Posts
- Dementia and Disability (APPG on Dementia / Alzheimer’s Society)
- Scoping Dimensions of Dementia-Friendly Organisations (JGCR / IES / Alzheimer’s Society / RCN / JRF)
- Facts and Figures on Unmet Needs in Older People in England (Age UK)
- Statistics on Unpaid Carers in the UK: Carers Rights Day 2019 (Carers UK)
- Dementia Risk Factors Re-Explored / Confirmed (NIHR Signal / BMJ Open)
Archives
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: NSAIDS: Non-Steroidal Anti-Inflammatory Drugs
Preventative Treatment to Reduce Risk of Alzheimer’s Disease, Using Non-Steroidal Anti-Inflammatory Drugs? (NHS Choices / Journal of Alzheimer’s Disease)
Summary A recent article suggests that use of nonsteroidal anti-inflammatory drugs (NSAIDs) might help to reduce the risk of developing Alzheimer’s Disease, if prescription were to be commenced years before clinical signs were to develop. An NHS Choices Behind the … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Aβ42, Alzheimer Disease Anti-Inflammatory Prevention, Alzheimer’s Disease Biomarkers, Amyloid Beta (Aβ42), Amyloid Beta Protein, Amyloid Cascade Inflammatory Hypothesis, Amyloid-β (Aβ), Amyloidogenic and Inflammatory Pathways, Aurin Biotech, Aurin Biotech Inc. Ltd. (Vancouver), ß-amyloid, Bazian, Behind the Headlines, Biomarkers, Canada, Critical Appraisals, Dementia Risk Reduction and Prevention, Dementia Saliva Testing (Pilot Study), Diagnosis of Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels, ELISA Method to Determine Aβ42 Levels in Saliva, Fluid Biomarker Analysis, Ibuprofen, Ibuprofen and the Reduced Risk of Alzheimer’s Disease Link, Inflammation, Journal of Alzheimer's Disease, Long-Term Ibuprofen Use, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroinflammation, Non-Invasive Biomarkers, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Preclinical Biomarkers in Alzheimer's Disease, Preventative Interventions, Prevention, Saliva Tests, Salivary Amyloid-β Protein 42 Levels, Salivary Biomarkers
|
Leave a comment
Further Press Releases and Documents Relating to the 2016 Alzheimer’s Association International Conference (Alzheimer’s Association International Conference)
Summary A list of press-releases is available relating to some of the main presentations at the Alzheimer’s Association International Conference, held in Toronto last week. Full Text Link Reference Alzheimer’s Association International Conference® 2016. List of Press Releases. [Toronto. Online]: … Continue reading →
Posted in Antipsychotics, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Statistics, Universal Interest
|
Tagged 2016 Alzheimer’s Association International Conference (AAIC®2016), ADAPT-FS Research Group, Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study (ADAPT-FS), Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Association, Alzheimer’s Association AAIC Press Office, Alzheimer’s Association International Conference® (AAIC®) 2016, Alzheimer’s Disease and Related Dementias (ADRD) Milestones (United States), Alzheimer’s Disease Research in Ibero America, Amyotrophic Lateral Sclerosis (ALS), Australian Reduction in Use of Antipsychotics in Dementia Care, Avoidable Hospital Admissions, Avoidable Hospitalizations of People With Alzheimer’s Disease: Cost to Medicare (USA), Behavioural and Psychological Symptoms of Dementia (BPSD), Beta-Amyloid PET Imaging, Canadian Research: Advances in Dementia Care, Celecoxib, Celecoxib (Selective COX-2 Inhibitor), Centro de Investigatición y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia-Related Misdiagnosis, Dementia-Related Misdiagnosis (Male), Disclosure, Disclosure of Risk Marker Status, Disclosure Protocols for Disclosing APOE Genotype for Risk of Dementia, Epidemiology of Alzheimer's disease in Ibero America, Estudio Nacional de Salud y Envejecimiento en México (ENASEM), Ethical Challenges in Preclinical Alzheimer’s Disease Studies and Trials, Ethical Considerations, Ethical Dilemmas, Ethics, Ethics and Consent, Eye Tests for Detection of Memory Decline and Dementia, Flanders-Belgian Patient Group, Formal Education and Complex Work (Cognitive Reserve), French Three-City Study, Frontotemporal Lobar Degeneration (FTLD), Genome-Wide Association Studies, Genome-Wide Association Studies (GWAS), Genome-Wide Association Study, Genotyping, Ibero America, International Genomics of Alzheimer's Project (IGAP), Latin America, Low Testosterone and Risk of Dementia, Men Receiving Dementia-Related Misdiagnoses More Than Women, Mild Behavioral Impairment (MBI), Milestones for Care and Support in U.S. National Plan to Address Alzheimer's Disease, Naproxen, Naproxen (Nonselective Cyclooxygenase [COX] Inhibitor), Neurodegeneration, Neurodegenerative Disease Research, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, p.R47H rs75932628 in TREM2 (Encoding the Triggering Receptor Expressed on Myeloid Cells 2 Gene on Chromosome 6p21), Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Reduction of Systematic Sedation in Dementia Care, Research and Development, Research and Innovation, Research Commitment, Risk Prevention, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), SABE (Salud Bienestar y Envejecimiento), Single SNP Associations in Flanders-Belgian AD Cohort, Smell and Eye Tests for Detection of Memory Decline and Dementia, Smell Tests For Detection of Memory Decline and Dementia, SNP rs75932628, Stopping Systemic Sedation, Systemic Sedation, Tau Pathogenesis, Tau Therapeutic Strategies, Testosterone Depletion and Increased Risk of Dementia, Three-City Study, Treating People with Alzheimer’s Disease Increases Survival and Reduces Cost of Care (vs. Non-Treatment), TREM2 R47H as a Risk Factor, USA National Plan to Address Alzheimer's Disease, Vascular Care Intervention To Prevent Dementia
|
Leave a comment
NICE Eyes on Evidence: Cumulative Index 2013 (NICE Evidence)
Summary The NICE Evidence‘s Eyes on Evidence service covers significant new evidence across a range of topics. Here is an alphabetical list of the items, which have appeared so far this year, of broad interest to readers of this information … Continue reading →
Posted in Acute Hospitals, Community Care, Depression, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Integrated Care, National, NHS Evidence, Parkinson's Disease, Physiotherapy, Quick Insights, Telecare, Telehealth, UK, Universal Interest
|
Tagged Acute Hospitals, Alternatives to Hospital Admission, Anti-Fat Bias, Anti-Fat Bias Among Doctors, Antibiotic-Associated Diarrhoea, Arrhythmia Care Coordinators, Atrial Fibrillation, Bed Days, Benzodiazepines, Benzodiazepines and Dementia, Cardiovascular Risk, Citalopram for Depression, Cognitive Decline, Cognitive Impairment, Cognitive Performance, Colloids, Computerised Reminders, Deep Brain Stimulation (DBS), Deep Brain Stimulation in Parkinson's Disease, Dietary Supplements, Domestic Violence, Domestic Violence in Primary Care, Dose Adjustment For Normal Eating (DAFNE), Drug Interactions, Drug Therapy for Mild Hypertension, Eyes on Evidence (NHS Evidence), Eyes on Evidence Issue 45 (January 2013), Eyes on Evidence Issue 46 (February 2013), Eyes on Evidence Issue 47 (March 2013), Eyes on Evidence Issue 48 (April 2013), Eyes on Evidence Issue 49 (May 2013), Eyes on Evidence Issue 50 (June 2013), Eyes on Evidence Issue 51 (July 2013), Eyes on Evidence Issue 52 (August 2013), Eyes on Evidence Issue 53 (September 2013), Fever in Patients with Cancer, General Health Checks in Adults, Grapefruit, Grapefruit: Drug Interactions, Harm Free Care, Health and Homelessness, Heart Failure, Herbal Remedies, Histopathology Management, Homelessness and Ill-Health, Hormone Replacement Therapy, Hospital Admission Rates, HRT, Hypoglycaemia, Infectious Diseases, Infectious Diseases Among Homeless Populations, Insomnia, Integrated Whole System Services for People With Dementia, Loneliness, Loneliness and Mortality in Older People, Loneliness and Social Isolation, Low-Risk Neutropenia, Metabolic Profile, Metabolic Profile and Declining Cognitive Function, Mild Cognitive Impairment, Mild Hypertension, Mortality in Older People, Musculoskeletal Physiotherapy, National Quitline, New Medicines in UK (Trends), NHS Safety Thermometer, NICE Evidence Updates, NICE Evidence’s Eyes on Evidence, NICE Eyes on Evidence, Non-Attendance, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Oral Antiseptics, Out of Hours Care, Patient Self-Referral, Physiotherapy for Parkinson's Disease, Podiatry Education, Podiatry Self-Care, Premature Death After Self-Harm, Preventable Deaths in English Acute Hospitals, Preventable Hospital Admissions, Probiotics, Problems in Care in English Acute Hospitals, Proton Pump Inhibitors (PPIs), Quality Innovation Productivity and Prevention (QIPP), Reducing Bed Days, Restless Legs Syndrome, Rheumatoid Arthritis, Rheumatoid Factor, Risk of asthma Inhaled Corticosteroids, Safety Express, Safety Thermometer, Screening for Type 2 Diabetes, Self-Care, Smoking, Social Isolation, Social Isolation and Mortality in Older People, Stable Asthma, Teledermatology, Telehealth and Emergency Care, Trans Fatty Acids, Type 1 Diabetes, Type 2 Diabetes, Ventilator-Associated Pneumonia, Warfarin Dosing Algorithm in Atrial Fibrillation. Eyes on Evidence Issue 51 (July 2013), Whole Systems Approach, Whole Systems Design, Wireless Working in Hospitals, Z Drugs
|
Leave a comment
Heart Risk Warning Over Painkiller Diclofenac (BBC News / MHRA)
Summary The medicines regulator has advised that the painkiller diclofenac should not be used by people with heart problems. A European review found a small increased risk of heart attack and stroke. “The Medicines and Healthcare Products Regulatory Agency (MHRA) said … Continue reading →
Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), In the News, Pain, Pharmacological Treatments, Quick Insights, Systematic Reviews, UK, Universal Interest
|
Tagged BBC Health News, Cerebrovascular Disease, Chronic Pain, Congestive Heart Failure, Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Coxibs, Diclofenac, Epidemiology and Statistics, Heart Attack or Stroke, Inflammatory Arthritis, Ischaemic Heart Disease, Lancet, Medicines and Healthcare Products Regulatory Agency (MHRA), Medicines Healthcare Products Regulatory Agency (MHRA), MHRA Drug Safety Updates, Musculoskeletal, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Osteoarthritis, Pain Management, Pain Relief, Peripheral Arterial Disease, Stroke, Systematic Reviews and Meta-Analyses
|
Leave a comment
High-Dose Painkiller Heart Risk (NHS Choices / BBC News)
Summary Commonly-used painkillers, such as ibuprofen and diclofenac, can increase the risk of heart problems slightly if taken in high doses over a long time. This conclusion was arrived at by meta-analysis of data from 639 separate clinical trials. The risks remain … Continue reading →
Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pain, Quick Insights, Systematic Reviews, UK, Universal Interest
|
Tagged BBC Health News, Behind the Headlines, Chronic Pain, Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Coxibs, Diclofenac, Epidemiology, Epidemiology and Statistics, Ibuprofen, Inflammatory Arthritis, Lancet, Musculoskeletal, Naproxen, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Osteoarthritis, Pain Management, Pain Relief, Systematic Reviews and Meta-Analyses, University of Oxford
|
Leave a comment
Aspirin, Steroidal and Non-Steroidal Anti-Inflammatory Drugs for Alzheimer’s Disease?
[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 8, March 2012]. Summary Inflammatory processes have previously been thought to play a role in the pathogenesis of Alzheimer’s Disease (AD). The authors of … Continue reading →
Posted in For Researchers (mostly), International, Pharmacological Treatments
|
Tagged Aceclofenac, Acemetacin, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Anti-Inflammatory, Aspirin, Bangkok and Baycrest Centre for Geriatric Care, Betamethasone, Celecoxib, Cortisone, COX-2 Inhibitors, Cyclooxygenase 2 Inhibitor, Deflazacort, Department of Family Medicine: Ramathibodi Hospital, Dexamethasone, Dexibruprofen, Dexketoprofen, Diclofenac Sodium, Diflunisal, Diflusinal, Etodolac, Etoricoxib, Fenbufen, Fenoprofen, Flurbiprofen, Hydrocortisone, Ibuprofen, Indometacin, Indomethacin, Ketoprofen, Lumiracoxib, Mahidol University, Mefenamic, Meloxicam, Methylprednisolone, Nabumetone, Naproxen, Nimesulide, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Old Age Psychiatry: Sussex Partnership NHS Foundation Trust, Piroxicam, Prednisone, Ramathibodi Hospital, Sulindac, Sussex Partnership NHS Foundation Trust, Tenoxicam, Tiaprofenic Acid, Triamcinolone, University of Toronto
|
Leave a comment
